Disseminated Aspergillosis as the Herald Manifestation of Chronic Granulomatous Disease in an Adult Patient
-
Ilad Alavi Darazam
,
Hossein Akhavan Zanjani
,
Davood Sanaee
,
Payam Tabarsi
,
Mostafa Alavi Moghaddam
,
Davood Mansouri
Abstract
Chronic granulomatous disease is an inherited defect in intracellular killing of ingested microorganisms characterized by recurrent life threatening bacterial and fungal infections including invasive aspergillosis in early childhood.
We report a disseminated aspergillosis as the representative of adult onset chronic granulomatous disease without previous infection, with dramatic response to combination of antifungal and interferon therapy.
1. Denning, D.W. Invasive aspergillosis. Clin Infect Dis 1998; 26(4):781-803.
2. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case- fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32(3):358-66.
3. Curntte JT. Chronic granulomatous disease, The solving of a clinical riddle at the molecular level. Clin Immunol Immunopathol 1993; 67(3 Pt 2):2–15.
4. Winkelstein JA, Marino MC, Johnston RB Jr, Boyle J, Curnutte J, Gallin JI, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000; 79(3):155-69.
5. Roos D, de Boer M, Kuribayashi F. Mutations in the X-linked and autosomal recessive forms of chronic granulomatous disease. Blood 1996; 87(5):1663-81.
6. Rae J, Newburger PE, Dinauer MC, Noack D, Hopkins PJ, Kuruto R, et al. X-Linked chronic granulomatous disease: mutations in the CYBB gene encoding the gp91-phox component of respiratory-burst oxidase. Am J Hum Genet 1998; 62(6):1320-31.
7. Ariga T, Furuta H, Cho K, Sakiyama Y. Genetic analysis of 13 families with X-linked chronic granulomatous disease reveals a low proportion of sporadic patients and a high proportion of sporadic carriers. Pediatr Res 1998; 44(1):85-92.
8. Dennis CG, Greco WR, Brun Y, Youn R, Slocum HK, Bernacki RJ, et al. Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/- mouse model of chronic granulomatous disease. Antimicrob Agents Chemother 2006;50(2):422-7.
9. O'Neil KM, Herman JH, Modlin JF, Moxon ER, Winkelstein JA. Pseudomonas cepacia: an emerging pathogen in chronic granulomatous disease. J Pediatr 1986; 108(6):940-2.
10. Speert DP, Bond M, Woodman RC, Curnutte JT.Infection with Pseudomonas cepacia in chronic granulomatous disease: role of nonoxidative killing by neutrophils in host defense. J Infect Dis 1994; 170(6):1524-31.
11. Liese J, Jansson A, Petropoulou Th, Kloos S, Belohradsky BH, Jendrossek V, et al. Chronic granulomatous disease in adults. The Lancet 1996;347(8996):220-3.
12. Curntte JT. Chronic granulomatous disease: The solving of a clinical riddle at the molecular level. Clin Immunol Immunopathol 1993; 67(3 Pt 2):S2–15.
13. Kobayashi S, Murayama S, Takanashi S, Takahashi K,Miyatsuka S, Fujita T, et al. Clinical features and prognoses of 23 patients with chronic granulomatous disease followed for 21 years by a single hospital in Japan. Eur J Pediatr 2008; 167(12):1389-94.
14. Martire B, Rondelli R, Soresina A, Pignata C, Broccoletti T, Finocchi A, et al. Clinical features, long- term follow-up and outcome of a large cohort of patients with Chronic Granulomatous Disease: an Italian multicenter study. Clin Immunol 2008;126(2):155-64.
15. Jones LB, McGrogan P, Flood TJ, Gennery AR, Morton L, Thrasher A, et al. Chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry. Clin Exp Immunol 2008; 152(2):211-8.
16. Soler-Palacin P, Margareto C, Llobet P, Asensio O,Hernandez M, Caragol I, et al. Chronic granulomatous disease in pediatric patients: 25 years of experience. Allergol Immunopathol (Madr) 2007; 35(3):83-9.
17. Khalilzadeh S, Bloorsaz MR, Mansouri D, Baghaie N, Hakimi S, Velayati AA. Clinical and Radiological Aspects of Chronic Granulomatous Disease in Children: A case Series from Iran. Iran J Allergy Asthma Immunol 2006; 5(2):85-8.
18. Tafti SF, Tabarsi P, Mansouri N, Mirsaeidi M, Motazedi Ghajar MA, Karimi S, et al. Chronic granulomatous disease with unusual clinical manifestation, outcome, and pattern of inheritance in an Iranian family. J Clin Immunol 2006; 26(3):291-6.
19. Movahedi M, Aghamohammadi A, Rezaei N,Shahnavaz N, Jandaghi AB, Farhoudi A, et al. Chronic granulomatous disease: a clinical survey of 41 patients from the Iranian primary immunodeficiency registry. Int Arch Allergy Immunol 2004; 134(3):253-9.
20. Aghamohammadi A, Moein M, Farhoudi A, Pourpak Z, Rezaei N, Abolmaali K, et al. Primary immunodeficiency in Iran: first report of the National Registry of PID in Children and Adults. J Clin Immunol 2002; 22(6):375-80.
21. Lun A, Roesler J, Renz H. Unusual late onset of X-linked chronic granulomatous disease in an adult woman after unsuspicious childhood. Clin Chem 2002;48(5):780-1.
22. Wolach B, Scharf Y, Gavrieli R, de Boer M, Roos D.Unusual late presentation of X-linked chronic granulomatous disease in an adult female with a somatic mosaic for a novel mutation in CYBB. Blood 2005; 105(1):61-6.
23. Schapiro BL, Newburger PE, Klempner MS, Dinauer MC. Chronic granulomatous disease presenting in a69-year-old man. N Engl J Med. 1991;325:1786-
1790.Pfaller MA, Messer SA, Hollis RJ, Jones RN; SENTRY Participants Group. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002; 46(4):1032-7.
24. Herbrecht R, Denning DW, Patterson TF, Bennett JE,Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347(6):408-15.
25. Denning DW, Ribaud P, Milpied N, Caillot D,Herbrecht R, Thiel E. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34(5):563-71.
26. Anaissie, EJ. Trial design for mold-active agents: time to break the mold--aspergillosis in neutropenic adults. Clin Infect Dis 2007; 44(10):1298-306.
27. Patterson TF, Kirkpatrick WR, White M, Hiemenz JW, Wingard JR, Dupont B, et al. Invasive aspergillosis: Disease spectrum, treatment practices, and outcomes. Medicine (Baltimore) 2000; 79(4):250-60.
28. Singh N. Invasive aspergillosis in organ transplant recipients: new issues in epidemiologic characteristics, diagnosis, and management. Med Mycol 2005;43(Suppl 1):S267-70.
29. Roilides E, Uhlig K, Venson D, Pizzo PA, Walsh TJ.Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun 1993; 61(4):1185-93.
30. Soncini E, Slatter MA, Jones LB, Hughes S, Hodges S, Flood TJ, et al. Unrelated donor and HLA-identical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth. Br J Haematol 2009; 145(1):73-83.
| Files | ||
| Issue | Vol 13, No 1 (2014) | |
| Section | Articles | |
| Keywords | ||
| Adulthood Anidulafungin Aspergillosis Chronic granulomatous disease Dihydrorhodamine Invasive fungal infection Voriconazole | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
